ERBB2 T862A

CI-VAR-00004349Explore in graph →NP_001276866.1:p.Thr862AlaNM_001289937.1:c.2584A>GCIViC 871

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
ERBB2 T862A	Lapatinib	Predictive	D	Supports Sensitivity Response	1	accepted	EID1986 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-T862A showed IC50 value of 125nM and IC90 of approximately 0.5 µM, and was considered as lapatinib-sensitive. Since levels of up to 1 µM of … (full text at CIViC) PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.